Fortis Healthcare Limited FORTIS NIFTY_MIDNSEPHARMA

Healthcare · Medical Care Facilities · India

https://www.fortishealthcare.com

Fortis Healthcare Limited operates as a healthcare delivery service provider in India. The company offers services in the areas of cardiac science, critical care, vascular surgery, dental science, dermatology, diabetology/endocrinology, emergency and trauma, geriatric medicine, liver transplant and hepatobiliary sciences, pain and palliative medicine, ENT, foetal medicine, gastroenterology and hepatology science, general surgery, and haematology areas. It also provides services in the areas of infertility medicine, internal medicine, mental health and behavioral science, nephrology, neuro surgery, neurointerventional radiology, neurology, obstetrics and gynaecology, oncology, ophthalmology, orthopedics, pediatrics, physiotherapy and rehabilitation, plastic and reconstructive surgery, pulmonology, radiology, organ transplant, rheumatology, thoracic surgery, transfusion medicine, urology, medical generics, endocrine surgery, and other support specialties, as well as treat infectious diseases. The company's healthcare verticals comprise hospitals, diagnostics, tertiary and quaternary care, and day care specialty facilities. Fortis Healthcare Limited was incorporated in 1996 and is based in Gurugram, India.

Market & Price

Market Cap

₹70,094.09 Cr

Current Price

₹928.45

High / Low (52W)

₹1,097.90 / ₹705.47

Beta

0.70

Valuation

Stock P/E

67.13

Industry PE

37.60

Forward P/E

39.65

PEG Ratio

0.42

Book Value

₹131.07

Price to Book

7.08

P/S

7.68

EV/EBITDA

35.15

Dividend Yield

0.11%

Profitability & Returns

ROCE

12.13%

ROE

11.01%

ROA

6.89%

Profit Margin

11.41%

Op Margin

17.35%

EPS (Latest Qtr)

₹3.52

EPS (TTM)

₹13.83

Balance Sheet & Liquidity

Debt/Equity

0.34

Quick Ratio

0.76

Current Ratio

0.86

Debt

₹3,472.58 Cr

Total Assets

₹15,966.23 Cr

Current Assets

₹1,819.42 Cr

Working Capital

₹-295.58 Cr

Ownership

Promoter Holding

35.19%

Chg in Prom Hold

FII / Inst Holding

48.20%

Chg in FII Hold

-0.02%

Financial Snapshot

Enterprise Value

₹73,278.80 Cr

Total Revenue (TTM)

₹9,127.84 Cr

EBITDA

₹2,084.98 Cr

Free Cash Flow

₹173.28 Cr

Operating Cash Flow

₹1,601.46 Cr

Shares Outstanding

₹75.50 Cr

Gross Margin

41.55%

Payout Ratio

7.25%

Growth (CAGR)

Revenue 5Y

13.68%

Profit 5Y

20.95%

Revenue (YoY)

17.80%

Earnings (YoY)

44.30%

PROS

Compounding revenue at 13.7% over 5 years.
Profit CAGR of 21.0% over 5 years.
Generates positive free cash flow.

CONS

Trading at a high P/E of 67.1.
In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

Price Chart

NSE TradingView Screener.in

Fundamental Growth

Period: Metric:

Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP ₹	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	FORTIS Fortis Healthcare Limited NIFTY_MIDNSEPHARMA	928.45	67.13	₹70,094.09 Cr	0.11%	12.13%	11.01%	13.68%	20.95%
2	SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA	1,799.20	37.59	₹4.32 L Cr	0.92%	17.94%	14.72%	10.39%	10.65%
3	DIVISLAB Divi's Laboratories Limited NSEPHARMA	6,667.00	68.97	₹1.77 L Cr	0.45%	18.96%	16.19%	11.27%	12.08%
4	TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA	4,410.80	68.96	₹1.49 L Cr	0.86%	9.06%	16.98%	13.27%	20.21%
5	CIPLA Cipla Limited NIFTY50NSEAIPHARMA	1,401.00	29.16	₹1.13 L Cr	0.93%	14.88%	11.74%	7.23%	11.45%
6	DRREDDY Dr. Reddy's Laboratories Limited NIFTY50NSEAIPHARMA	1,303.50	25.90	₹1.09 L Cr	0.61%	14.00%	11.83%	10.96%	-2.35%
7	ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA	1,077.70	21.51	₹1.08 L Cr	0.09%	19.24%	18.32%	16.55%	36.99%
8	LUPIN Lupin Limited NIFTY_MIDNSEPHARMA	2,267.70	19.49	₹1.04 L Cr	0.53%	28.42%	26.91%	19.10%	131.46%
9	MANKIND Mankind Pharma Limited NIFTY_MIDNSEPHARMA	2,375.60	51.29	₹98,090.71 Cr	0.08%	13.78%	12.45%	17.73%	14.28%

Quarterly Results

Figures in INR.

Metric	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Revenue	-	-	2,007.20 Cr	2,166.72 Cr	2,331.44 Cr	2,265.01 Cr	2,364.67 Cr
Cost of Revenue	-	-	877.56 Cr	975.20 Cr	1,033.48 Cr	1,009.68 Cr	1,020.15 Cr
Gross Profit	-	-	1,129.64 Cr	1,191.52 Cr	1,297.96 Cr	1,255.33 Cr	1,344.52 Cr
Operating Expenses	-	-	796.40 Cr	802.33 Cr	847.47 Cr	869.82 Cr	934.16 Cr
Operating Income	-	-	333.24 Cr	389.19 Cr	450.49 Cr	385.51 Cr	410.36 Cr
EBITDA	-	-	406.34 Cr	521.62 Cr	606.12 Cr	471.56 Cr	530.45 Cr
Interest Expense	-	-	67.56 Cr	69.57 Cr	74.88 Cr	85.74 Cr	84.28 Cr
Pretax Income	-	-	236.55 Cr	350.57 Cr	425.40 Cr	265.68 Cr	324.20 Cr
Tax Provision	-	-	48.53 Cr	83.79 Cr	96.58 Cr	68.28 Cr	53.01 Cr
Net Income	-	-	183.89 Cr	260.28 Cr	321.92 Cr	193.73 Cr	265.85 Cr
Diluted EPS	-	-	2.44	3.45	4.26	2.57	3.52

Profit & Loss (Annual)

Figures in INR.

Metric	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Revenue	-	6,213.15 Cr	6,835.09 Cr	7,782.75 Cr	9,127.84 Cr
Cost of Revenue	-	2,839.02 Cr	3,155.43 Cr	3,460.81 Cr	4,038.51 Cr
Gross Profit	-	3,374.13 Cr	3,679.66 Cr	4,321.94 Cr	5,089.33 Cr
Operating Expenses	-	2,603.89 Cr	2,767.38 Cr	3,119.61 Cr	3,453.78 Cr
Operating Income	-	770.24 Cr	912.28 Cr	1,202.33 Cr	1,635.55 Cr
EBITDA	-	1,237.80 Cr	1,308.51 Cr	1,577.06 Cr	2,129.75 Cr
Interest Expense	-	108.39 Cr	108.05 Cr	184.41 Cr	314.47 Cr
Pretax Income	-	813.68 Cr	857.97 Cr	1,007.04 Cr	1,365.85 Cr
Tax Provision	-	180.70 Cr	212.75 Cr	197.66 Cr	301.66 Cr
Net Income	-	588.73 Cr	598.88 Cr	774.21 Cr	1,041.78 Cr
Diluted EPS	7.35	7.80	7.93	10.26	-

Compounded Sales Growth

5 Years:	13.68%
1 Year:	17.80%

Compounded Profit Growth

5 Years:	20.95%
1 Year:	44.30%

Stock Price Performance

1 Year:	+29.77%
6 Months:	+0.87%
3 Months:	+0.97%
1 Month:	+0.60%

Balance Sheet (Annual)

Figures in INR.

Metric	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Total Assets	-	12,433.60 Cr	13,288.78 Cr	13,691.53 Cr	15,966.23 Cr
Current Assets	-	1,406.35 Cr	1,420.59 Cr	1,471.36 Cr	1,819.42 Cr
Cash & Equivalents	-	141.08 Cr	235.27 Cr	139.72 Cr	406.97 Cr
Inventory	-	122.84 Cr	107.42 Cr	115.29 Cr	135.27 Cr
Receivables	-	510.08 Cr	555.81 Cr	711.45 Cr	1,043.76 Cr
Total Liabilities	-	4,333.22 Cr	4,732.64 Cr	4,522.14 Cr	5,797.72 Cr
Current Liabilities	-	1,425.88 Cr	3,170.17 Cr	1,607.31 Cr	2,115.00 Cr
Long Term Debt	-	572.22 Cr	740.85 Cr	2,085.72 Cr	2,401.16 Cr
Total Debt	-	925.72 Cr	1,155.02 Cr	2,475.11 Cr	3,472.58 Cr
Total Equity	-	7,242.26 Cr	7,662.90 Cr	8,916.52 Cr	9,895.55 Cr
Shares Outstanding	-	75.50 Cr	75.50 Cr	75.50 Cr	75.50 Cr

Cash Flows (Annual)

Figures in INR.

Metric	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Operating Cash Flow	-	822.25 Cr	1,100.10 Cr	1,423.93 Cr	1,601.46 Cr
Investing Cash Flow	-	-373.70 Cr	-886.37 Cr	-779.38 Cr	-1,538.41 Cr
Financing Cash Flow	-	-471.22 Cr	-86.46 Cr	-713.84 Cr	163.76 Cr
Capital Expenditure	-	-447.24 Cr	-942.47 Cr	-846.93 Cr	-945.44 Cr
Free Cash Flow	-	375.01 Cr	157.63 Cr	577.00 Cr	656.02 Cr
Net Change in Cash	-	-22.67 Cr	127.27 Cr	-69.29 Cr	226.81 Cr

Ratios (Annual)

Figures in %.

Metric	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Gross Margin %	-	54.3%	53.8%	55.5%	55.8%
Operating Margin %	-	12.4%	13.3%	15.4%	17.9%
Net Margin %	-	9.5%	8.8%	9.9%	11.4%
ROE %	-	8.1%	7.8%	8.7%	10.5%
ROCE %	-	7.0%	9.0%	9.9%	11.8%

Shareholding Pattern

Insiders

35.19%

Institutions

48.20%

Public Float

74.37%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for FORTIS

No recent headlines available.

FORTIS · Healthcare